Press Releases InMed to Participate in Upcoming Investor Events March 7, 2023 Read More » InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update February 17, 2023 Read More » InMed Submits Form 12b-25 February 9, 2023 Read More » InMed Provides Business Update and Milestones for 2023 January 10, 2023 Read More » InMed Announces Results of 2022 Annual General Meeting December 15, 2022 Read More » InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor December 12, 2022 Read More » InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market November 21, 2022 Read More » InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market November 18, 2022 Read More » InMed Provides Update on Management Changes November 17, 2022 Read More » InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada (“NSERC”) Alliance Grant Funding November 16, 2022 Read More » InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update November 11, 2022 Read More » Registration Now Open For Tribe Public’s Webinar Event “Exploring the Neuroprotective Qualities of Rare Cannabinoids” Featuring InMed’s Management Team On November 17, 2022 November 10, 2022 Read More » InMed Pharmaceuticals Supports Epidermolysis Bullosa Awareness Week October 26, 2022 Read More » InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update September 23, 2022 Read More » InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market September 13, 2022 Read More » InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market September 9, 2022 Read More » InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business September 8, 2022 Read More » InMed Announces Share Consolidation to Meet Nasdaq Listing Criteria August 23, 2022 Read More » InMed Announces Changes to its Board of Directors August 9, 2022 Read More » InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa July 25, 2022 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Next » Management Learn More Board of Directors Learn More Scientific Advisory Board Learn More Investor Alerts Sign up to receive news releases from InMed Pharmaceuticals. SIGN UP
InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update February 17, 2023 Read More »
InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor December 12, 2022 Read More »
InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market November 21, 2022 Read More »
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market November 18, 2022 Read More »
InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada (“NSERC”) Alliance Grant Funding November 16, 2022 Read More »
InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update November 11, 2022 Read More »
Registration Now Open For Tribe Public’s Webinar Event “Exploring the Neuroprotective Qualities of Rare Cannabinoids” Featuring InMed’s Management Team On November 17, 2022 November 10, 2022 Read More »
InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update September 23, 2022 Read More »
InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market September 13, 2022 Read More »
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market September 9, 2022 Read More »
InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business September 8, 2022 Read More »
InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa July 25, 2022 Read More »
